Abbott Laboratories (ABT) · Oct 21, 2026 · Earnings
In line — Adjusted EPS $1.42 vs ~$1.42 consensus
Abbott’s Q3 earnings matched adjusted EPS expectations and slightly beat revenue views, while Exact Sciences fueled growth but lifted costs and charges.
Abbott is integrating Exact Sciences into a new cancer-diagnostics growth platform while relying on Medical Devices, Libre, and cardiac technologies for organic expansion; the acquisition is also increasing amortization and financing costs.
The quarter was essentially in line, not a clean beat. Adjusted diluted EPS came in at $1.42, exactly matching the published consensus of roughly $1.42, while revenue of $13.013 billion was modestly above the approximately $12.99 billion expectation. Comparable sales growth was 7.0%, showing the underlying business expanded at a healthy but not surprising pace.
| $ millions except EPS | 3Q26 | 3Q25 | Expectation |
|---|---|---|---|
| Net sales | $13,013 | $11,369 | ~$12,990 |
| Adjusted diluted EPS | $1.42 | $1.30 | ~$1.42 |
| GAAP diluted EPS | $0.53 | $0.94 | — |
| Comparable sales growth | 7.0% | — | — |
| Diagnostics comparable growth | 6.4% | — | — |
| Medical Devices comparable growth | 7.8% | — | — |
The growth engine is becoming clearer. Diagnostics reported sales jumped 46.7%, but the more useful comparable figure was 6.4% after including Exact Sciences in the prior-year comparison. Cancer Diagnostics grew 13.8% comparably, while Medical Devices delivered 7.8% comparable growth, led by Electrophysiology and Diabetes Care.
The headline GAAP collapse mostly reflects acquisition and legal costs, but the costs are still real. GAAP EPS fell to $0.53 from $0.94, with $841 million of intangible amortization and approximately $670 million of legal settlements among the specified items. Interest expense also rose to $297 million from $44 million, consistent with the heavier financing burden created by the Exact Sciences transaction.
The filing does not introduce a new full-year earnings target. That leaves the central question unchanged: whether Exact Sciences’ faster growth and Abbott’s product launches can increasingly offset the acquisition’s amortization, interest, integration, and legal-cost drag. Abbott’s recently highlighted pipeline includes Libre Duo, Amulet 360, and TactiFlex Duo, making commercialization and adoption of those products the next operating proof points.
Bottom line: This was a credible growth quarter but not an earnings surprise: revenue edged ahead, adjusted EPS met expectations, and the strategic growth areas are working. The result advances Abbott’s story modestly, while the acquisition-related cost burden remains a material part of it.
Q4 report; U.S. launches of Libre Duo and TactiFlex Duo
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!